Subtopic Deep Dive

← Studies on Chitinases and Chitosanases

Chitinases as Disease Biomarkers
Research Guide

What is Chitinases as Disease Biomarkers?

Chitinases as disease biomarkers refers to the use of chitinase enzymes and chitinase-like proteins, such as chitotriosidase (CHIT1) and YKL-40, as measurable serum indicators for diagnosing and monitoring diseases including Gaucher disease, sarcoidosis, ALS, and cancer.

Researchers measure elevated chitinase levels in patient sera to detect lysosomal storage disorders like Gaucher disease and neurodegenerative conditions like ALS. Chitotriosidase activity serves as a primary biomarker in Gaucher disease diagnostics (Aerts et al., 2011, 116 citations). Over 10 key papers from 2007-2021 document chitinases' roles in inflammation, fungal infections, and cancer progression, with foundational works exceeding 100 citations each.

Curated Papers

Key Challenges

Why It Matters

Chitinases enable non-invasive monitoring of Gaucher disease progression, where chitotriosidase levels correlate with disease severity and treatment response (Aerts et al., 2011; Nagral, 2014). In ALS, cerebrospinal fluid CHIT1 levels predict disease progression and staging (Steinacker et al., 2017; Varghese et al., 2013). Cancer studies link chitinase-like proteins such as YKL-40 and CHI3L1 to tumor progression and immunotherapy response, supporting prognostic models (Kzhyshkowska et al., 2007; Ma et al., 2021). These biomarkers reduce reliance on invasive biopsies, improving clinical outcomes in chitin-related disorders.

Key Research Challenges

Biomarker Specificity

Chitinases elevate in multiple conditions including Gaucher disease, ALS, and cancer, complicating disease-specific diagnosis (Kzhyshkowska et al., 2007). Distinguishing CHIT1 signals from background inflammation requires longitudinal studies (Steinacker et al., 2017). Assay standardization across labs remains inconsistent (Aerts et al., 2011).

Prognostic Validation

Longitudinal data linking chitinase levels to outcomes like ALS progression or cancer survival are limited to small cohorts (Varghese et al., 2013; Ma et al., 2021). Predictive models need larger validation sets (Kanneganti, 2012). Variability in enzyme activity assays hinders reliability (Aerts et al., 2011).

Mechanistic Understanding

Roles of chitinase-like proteins like YKL-40 in non-enzymatic functions such as PD-L1 regulation in cancer are unclear (Ma et al., 2021). Chi-lectins lack hydrolytic activity yet indicate pathology (Bussink et al., 2007). Integrating chitinase evolution with disease mechanisms requires multi-omics approaches (Kanneganti, 2012).

Essential Papers

Evolution of Mammalian Chitinase(-Like) Members of Family 18 Glycosyl Hydrolases

Anton P. Bussink, Dave Speijer, Johannes M. F. G. Aerts et al. · 2007 · Genetics · 292 citations

Abstract Family 18 of glycosyl hydrolases encompasses chitinases and so-called chi-lectins lacking enzymatic activity due to amino acid substitutions in their active site. Both types of proteins wi...

Chitinases—Potential Candidates for Enhanced Plant Resistance towards Fungal Pathogens

Manish Kumar, Amandeep Singh Brar, Monika Yadav et al. · 2018 · Agriculture · 188 citations

Crop cultivation is crucial for the existence of human beings, as it fulfills our nutritional requirements. Crops and other plants are always at a high risk of being attacked by phytopathogens, esp...

Human chitinases and chitinase-like proteins as indicators for inflammation and cancer.

Julia Kzhyshkowska, Alexei Gratchev, Sergij Goerdt · 2007 · PubMed · 157 citations

Human Glyco_18 domain-containing proteins constitute a family of chitinases and chitinase-like proteins. Chitotriosidase and AMCase are true enzymes which hydrolyse chitin and have a C-terminal chi...

Role of Chitotriosidase (Chitinase 1) Under Normal and Disease Conditions

Manasa Kanneganti · 2012 · Journal of Epithelial Biology & Pharmacology · 145 citations

Mammalian chitinases belong to the glycosyl hydrolase 18 family based on structural homology and the family includes a large number of bacterial and eukaryotic chitinases. Among the mammalian chiti...

Chitin, Chitinase Responses, and Invasive Fungal Infections

Karina Vega, Markus Kalkum · 2011 · International Journal of Microbiology · 128 citations

The human immune system is capable of recognizing and degrading chitin, an important cell wall component of pathogenic fungi. In the context of host-immune responses to fungal infections, herein we...

Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression

Petra Steinacker, Federico Verde, Lubin Fang et al. · 2017 · Journal of Neurology Neurosurgery & Psychiatry · 120 citations

Objectives Neurochemical markers of amyotrophic lateral sclerosis (ALS) that reflect underlying disease mechanisms might help in diagnosis, staging and prediction of outcome. We aimed at determinin...

Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies

Johannes M. F. G. Aerts, Wouter W. Kallemeijn, Wouter Wegdam et al. · 2011 · Journal of Inherited Metabolic Disease · 116 citations

Abstract A biomarker is an analyte indicating the presence of a biological process linked to the clinical manifestations and outcome of a particular disease. In the case of lysosomal storage disord...

Reading Guide

Foundational Papers

Start with Bussink et al. (2007, 292 citations) for chitinase family evolution and chi-lectins; Kzhyshkowska et al. (2007, 157 citations) for human chitinases in inflammation/cancer; Aerts et al. (2011, 116 citations) for Gaucher biomarker validation.

Recent Advances

Study Steinacker et al. (2017, 120 citations) for ALS CSF CHIT1 correlations; Ma et al. (2021, 102 citations) for CHI3L1 in cancer immunotherapy; Varghese et al. (2013, 108 citations) for sporadic ALS chitotriosidase.

Core Methods

Enzyme assays (CHIT1 activity on fluorogenic substrates); ELISA for YKL-40/CHI3L1; longitudinal serum/CSF sampling with statistical modeling for prognostic value (Aerts et al., 2011; Steinacker et al., 2017).

How PapersFlow Helps You Research Chitinases as Disease Biomarkers

Discover & Search

Research Agent uses searchPapers('chitotriosidase Gaucher disease biomarker') to retrieve 20+ papers including Aerts et al. (2011), then citationGraph reveals connections to Steinacker et al. (2017) on ALS. findSimilarPapers on Kzhyshkowska et al. (2007) uncovers cancer biomarker extensions, while exaSearch handles niche queries like 'CHI3L1 PD-L1 chitinase cancer'.

Analyze & Verify

Analysis Agent applies readPaperContent on Steinacker et al. (2017) to extract CHIT1 CSF correlations, then verifyResponse (CoVe) cross-checks claims against Varghese et al. (2013). runPythonAnalysis processes biomarker datasets for statistical significance (e.g., t-tests on chitinase levels), with GRADE grading assigning high evidence to Gaucher diagnostics from Aerts et al. (2011).

Synthesize & Write

Synthesis Agent detects gaps like missing ALS-cancer chitinase comparisons, flags contradictions in YKL-40 roles (Kzhyshkowska et al., 2007 vs. Ma et al., 2021), and generates exportMermaid diagrams of biomarker pathways. Writing Agent uses latexEditText for biomarker review sections, latexSyncCitations to integrate 15 papers, and latexCompile for publication-ready manuscripts.

Use Cases

"Analyze CHIT1 levels across Gaucher and ALS patient datasets for correlation stats."

Research Agent → searchPapers → runPythonAnalysis (pandas correlation matrix on extracted data from Aerts et al. 2011 and Steinacker et al. 2017) → matplotlib plots of biomarker trends.

"Draft LaTeX review on chitinases in cancer biomarkers citing Kzhyshkowska 2007."

Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (15 papers) → latexCompile → PDF with chitinase pathway figure.

"Find code for chitinase activity assays from recent papers."

Research Agent → paperExtractUrls (from Kanneganti 2012) → paperFindGithubRepo → githubRepoInspect → exportPythonCode for enzymatic assay simulations.

Automated Workflows

Deep Research workflow scans 50+ chitinase papers via searchPapers, structures Gaucher biomarker report with GRADE scores from Aerts et al. (2011). DeepScan's 7-step chain verifies ALS progression claims (Steinacker et al., 2017) using CoVe checkpoints and runPythonAnalysis for survival correlations. Theorizer generates hypotheses on CHI3L1-PD-L1 links from Ma et al. (2021) literature synthesis.

Try Doxa for Chitinases as Disease Biomarkers Research

Frequently Asked Questions

What defines chitinases as disease biomarkers?

Chitinases like CHIT1 and chitinase-like proteins (YKL-40, CHI3L1) are serum/CSF analytes elevated in Gaucher, ALS, sarcoidosis, and cancer, correlating with disease activity (Kzhyshkowska et al., 2007; Aerts et al., 2011).

What methods measure chitinase biomarkers?

Enzyme activity assays quantify CHIT1 hydrolysis of 4-methylumbelliferyl chitotrioside; immunoassays detect YKL-40 levels. Longitudinal serum/CSF sampling tracks progression (Steinacker et al., 2017; Varghese et al., 2013).

What are key papers on chitinases as biomarkers?

Foundational: Bussink et al. (2007, 292 citations) on evolution; Kzhyshkowska et al. (2007, 157 citations) on inflammation/cancer. Recent: Steinacker et al. (2017, 120 citations) ALS; Ma et al. (2021, 102 citations) CHI3L1-cancer.

What open problems exist in chitinase biomarkers?

Specificity across diseases, standardized assays, and mechanistic links to outcomes like cancer immunotherapy response remain unresolved (Ma et al., 2021; Kanneganti, 2012).